Steven D. Knight

2.1k citations

29 papers · 610 indexed · h-index 12

Co-authors: Larry E. Overman Garry Pairaudeau Cynthia A. Parrish Dashyant Dhanak Robert W. Marquis Steven R. Angle John M. Fevig Stephen A. Douglas
Topics: Epigenetics and DNA Methylation (4 papers)Chemical synthesis and alkaloids (4 papers)Chemical Synthesis and Analysis (3 papers)
Cited by: Pharmacology Organic Chemistry
Journals: Journal of the American Chemical Society The Journal of Experimental Medicine British Journal of Pharmacology
Partner nations: United States United Kingdom Poland

In The Last Decade

Steven D. Knight

27 papers receiving 582 citations

Peers

Countries citing papers authored by Steven D. Knight

Since Specialization

Citations

This map shows the geographic impact of Steven D. Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven D. Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven D. Knight more than expected).

Fields of papers citing papers by Steven D. Knight

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven D. Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven D. Knight. The network helps show where Steven D. Knight may publish in the future.

Co-authorship network of co-authors of Steven D. Knight

This figure shows the co-authorship network connecting the top 25 collaborators of Steven D. Knight. A scholar is included among the top collaborators of Steven D. Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven D. Knight. Steven D. Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Asymmetric synthesis of potent and orally bioavailable thiophene-based EZH2 inhibitors 2025 ·Bioorganic & Medicinal Chemistry Letters ·Xinrong Tian,K. A. NEWLANDER,Louis V. LaFrance,(unknown),James Brackley,Charles F. McHugh,Yanan He,Neil W. Johnson,(unknown),Melissa B. Pappalardi,Michael T. McCabe,Steven D. Knight	1
2	Improving Network Availability with Protective ReRoute 2023 ·David Wetherall,Abdul Kabbani,Van Jacobson,(unknown),(unknown),Charles B. Morrey,(unknown),Phillipa Gill,Steven D. Knight,Amin Vahdat	3
3	A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose 2021 ·Expert Review of Clinical Pharmacology ·(unknown),Tianrui Yang,(unknown),Steven D. Knight	3
4	Opioid Overdoses for Recently Incarcerated Individuals: Toxicology Results and Risk Evaluations 2020 ·Substance Use & Misuse ·(unknown),Jacob Shreffler,Steven D. Knight,(unknown),Martin Huecker	0
5	Signaling function of PRC2 is essential for TCR-driven T cell responses 2018 ·The Journal of Experimental Medicine ·Marc‐Werner Dobenecker,Joon Seok Park,(unknown),Michael T. McCabe,Richard Gregory,Steven D. Knight,Inmaculada Rioja,Anna K. Bassil,Rab K. Prinjha,Alexander Tarakhovsky	38
6	Medical Mimics of Psychiatric Conditions, Part 2 2016 ·Steven D. Knight,Martin Huecker,(unknown)	2
7	A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation 2014 ·Molecular Cancer Therapeutics ·Heidi M. Ott,Alan P. Graves,Melissa B. Pappalardi,Michael J. Huddleston,Wendy S. Halsey,Ashley M. Hughes,Arthur Groy,Edward Dul,Yong Jiang,Yuchen Bai,Roland S. Annan,Sharad K. Verma,Steven D. Knight,Ryan G. Kruger,Dashyant Dhanak,Benjamin Schwartz,Peter J. Tummino,Caretha L. Creasy,Michael T. McCabe	35
8	Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP 2008 ·Current Topics in Medicinal Chemistry ·Steven D. Knight,Cynthia A. Parrish	46
9	Urotensin-II receptor antagonists: Synthesis and SAR of N-cyclic azaalkyl benzamides 2008 ·Bioorganic & Medicinal Chemistry Letters ·Jian Jin,Ming An,Anthony Sapienza,Nambi Aiyar,Diane P. Naselsky,Henry M. Sarau,James J. Foley,Kevin L. Salyers,Steven D. Knight,Richard M. Keenan,Ralph A. Rivero,Dashyant Dhanak,Stephen A. Douglas	14
10	A novel synthesis of substituted 4H-pyrazolo[3,4-d]pyrimidin-4-ones 2007 ·Tetrahedron Letters ·Nicholas D. Adams,Stanley J. Schmidt,Steven D. Knight,Dashyant Dhanak	5
11	A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A), demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro 2007 ·David Sutton,Aidan G. Gilmartin,(unknown),Chiu-Mei Sung,Lusong Luo,Jeffrey D. Carson,Sylvie Laquerre,William D. Cornwell,Andrew King,Steven D. Knight,Dashyant Dhanak,Gustave Bergnes,Xiangping Qian,Penelope Chua,Kenneth W. Wood,Pearl S. Huang,Barbara Weber,Robert Copeland,(unknown)	5
12	A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer 2006 ·Jeffrey R. Jackson,Aidan G. Gilmartin,(unknown),Steven D. Knight,(unknown),Lusong Luo,David Sutton,Eian Caulder,Melody Diamond,(unknown),ShuYun Zhang,Pearl S. Huang,Gustave Bergnes,Andrew McDonald,Yan Lee,Roman Sakowicz,Kenneth W. Wood	11
13	Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Jian Jin,Dashyant Dhanak,Steven D. Knight,Katherine L. Widdowson,Nambi Aiyar,Diane P. Naselsky,Henry M. Sarau,James J. Foley,Dulcie B. Schmidt,Carl D. Bennett,Bing Wang,Gregory L. Warren,M. Lane Moore,Richard M. Keenan,Ralph A. Rivero,Stephen A. Douglas	17
14	Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist 2002 ·British Journal of Pharmacology ·David J. Behm,Christopher L. Herold,Eliot H. Ohlstein,Steven D. Knight,Dashyant Dhanak,Stephen A. Douglas	42
15	Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2 2001 ·Bioorganic & Medicinal Chemistry Letters ·Dashyant Dhanak,(unknown),Michael G. Darcy,Richard M. Keenan,Steven D. Knight,(unknown),Lance H. Ridgers,Henry M. Sarau,(unknown),John R. White,Lily Zhang	23
16	RCN (Royal College of Nursing) A&E Nursing Association. Adolescent's in A&E. A position statement. 1999 ·PubMed ·(unknown),(unknown),Steven D. Knight,(unknown),(unknown),(unknown),Maire Horstman	3
17	The design and synthesis of 2,5-linked pyrrolinones. A potential non-peptide peptidomimetic scaffold 1996 ·Bioorganic & Medicinal Chemistry ·Amos B. Smith,Steven D. Knight,Paul A. Sprengeler,Ralph Hirschmann	21
18	The enantiomer of strychnine is a weak antagonist of the inhibitory glycine receptor 1995 ·Bioorganic & Medicinal Chemistry Letters ·Steven D. Knight,Ricardo Miledi,Nguyêñ Quôć Thǎńg,Larry E. Overman,Garry Pairaudeau	4
19	Asymmetric Total Syntheses of (-)- and (+)-Strychnine and the Wieland-Gumlich Aldehyde 1995 ·Journal of the American Chemical Society ·Steven D. Knight,Larry E. Overman,Garry Pairaudeau	103
20	Synthesis applications of cationic aza-Cope rearrangements. 24. The aza-Cope-Mannich approach to Strychnos alkaloids. Short stereocontrolled total syntheses of (.+-.)-dehydrotubifoline and (.+-.)-akuammicine 1993 ·Journal of the American Chemical Society ·Steven R. Angle,John M. Fevig,Steven D. Knight,Robert W. Marquis,Larry E. Overman	62

About Steven D. Knight

Steven D. Knight is a scholar working on Pharmacology, Toxicology and Development, having authored 29 papers that have together received 610 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (4 papers), Chemical synthesis and alkaloids (4 papers) and Chemical Synthesis and Analysis (3 papers). The work is most often cited by research in Pharmacology (122 citations), Organic Chemistry (327 citations) and Pharmacology (86 citations). Steven D. Knight has collaborated with scholars based in United States, United Kingdom and Poland. Frequent co-authors include Larry E. Overman, Garry Pairaudeau, Cynthia A. Parrish, Dashyant Dhanak, Robert W. Marquis, Steven R. Angle, John M. Fevig, Stephen A. Douglas, David J. Behm and Eliot H. Ohlstein. Their work appears in journals such as Journal of the American Chemical Society, The Journal of Experimental Medicine and British Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact